- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00125489
CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi
August 26, 2010 updated by: National Institute of Allergy and Infectious Diseases (NIAID)
Chloroquine and Sulfadoxine-Pyrimethamine Efficacy for the Treatment of Uncomplicated Falciparum Malaria in Blantyre, Malawi
The purpose of this research study is to find out how well chloroquine works as a drug to treat malaria in children, compared to the standard malaria treatment in Malawi.
In preparation for a longer study of the malaria treatment medication chloroquine alone and in combination with other drugs, a shorter pre-study will be done to compare the anti-malarial effectiveness of chloroquine versus sulfadoxine-pyrimethamine (SP), the standard treatment in Malawi.
Two hundred ten children, ages 6 months to 12 years, around Blantyre, Malawi, will be given standard dosing of either chloroquine or SP when they come to the Ndirande Health Centre with signs or symptoms consistent with malaria.
The first 30 participants in each treatment group will remain under continuous observation at the health center so that the researchers can monitor their response to the medication until the infection goes away.
The participants will be followed for 28 days to see if the the treatment works or fails.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study follows the observation that chloroquine-resistant malaria may have returned to Malawi, 10 years after its use was eliminated.
There is growing consensus that combination chemotherapy should be the rule in malaria treatment to deter the development of drug resistance and possibly also decrease malaria transmission.
As sulfadoxine-pyrimethamine (SP) failure rates increase, the reintroduction of chloroquine in Malawi in combination with highly effective rapidly acting drugs such as artesunate and chlorproguanil-dapsone should be considered, and would likely extend the useful life span of each of the drugs.
In preparation for a longitudinal clinical trial of chloroquine alone and SP in combination with other drugs, a preliminary trial will be conducted to compare the anti-malarial efficacy of chloroquine versus SP, the standard treatment in Malawi.
This is a randomized, open-label clinical trial to compare the antimalarial efficacy of chloroquine versus SP among children with uncomplicated malaria in Blantyre, Malawi.
In this study, 210 peri-urban children will be randomly assigned to receive standard dosing of either chloroquine or SP.
Follow up will consist of visits on days 2, 3, 7, 14, 21 and 28, according to the standard World Health Organization protocol.
Because chloroquine has not been used to treat malaria in Malawi for over a decade, special safety precautions will be taken at the beginning of the study.
The first 30 participants in each arm will remain at the Health Centre under continuous observation of the medical staff to monitor response to therapy until they are afebrile for 12 hours and have two consecutive negative 12-hourly blood smears.
Observation in an inpatient setting will also help to avoid potential bias due to more intense follow-up of the hospitalized group.
A Safety Monitoring Committee (SMC) will meet after the first 30 participants have been enrolled in each arm to determine if the study should stop continuous observation and proceed with out-patient follow up only.
All participants will be followed for 28 days to monitor for late therapeutic or parasitologic failure.
The primary study objective is to assess the efficacy of chloroquine compared with standard SP therapy, in treating malaria in Malawi, where chloroquine has not been used for over 10 years and to compare it to the efficacy of standard therapy with SP.
The secondary study objective is to assess the effect of the re-introduction of chloroquine on the molecular markers associated with chloroquine resistance.
The primary study endpoint is the rates of adequate clinical and parasitologic response to therapy.
The secondary study endpoints are: (1) rates of early and late therapeutic failure; (2) rates of early and late parasitologic failure; (3) prevalence of chloroquine-resistance conferring pfcrt K76T mutation in pre-treatment infections; (4) rates of pre- and post-treatment pfcrt K76T mutation in cases of chloroquine treatment failure; (5) prevalence of SP-resistance conferring dhfr/dhps mutations in pre-treatment infections; (6) rates of pre- and post-treatment dhfr/dhps mutations in cases of SP treatment failure; (7) clearance time of parasitemia; (8) clearance time of fever; and (9) presence of post-treatment anemia.
Study Type
Interventional
Enrollment
210
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Blantyre, Malawi
- Blantyre Malaria Project
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 months to 12 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Patients aged >= 6 months to 12 years presenting to Ndirande Health Centre with signs or symptoms consistent with malaria including but not limited to one or more of the following:
- fever at the time of evaluation (axillary temperature 37.5° C by digital thermometer)
- report of fever within the last two days
- profound anemia (conjunctival or palmar pallor)
- headache
- body aches
- abdominal pain
- decreased intake of food or fluids
- weakness
- Positive malaria smear for P. falciparum mono-infection
- Parasite density of 2,000-200,000/microliter or < 10%
- Willingness to remain at the Health Centre under continuous observation until the resolution of the infection
- Parental consent for each participant, and child assent for children older than 5 years
Exclusion Criteria:
Signs of severe malaria: One or more of the following:
- hemoglobin < 5 g/dl
- parasitemia > 10%
- prostration * as indicated by inability to drink or breastfeed
- respiratory distress (deep Kussmaul respirations)
- bleeding
- recent seizures*, coma* or mental obtundation* (Blantyre coma score less than 5)
- persistent vomiting*
- Presence of a severe disease
- Presence of a febrile condition caused by diseases other than malaria
- Known allergy or history of adverse reaction to sulfadoxine/pyrimethamine (SP), sulfa drugs or chloroquine
- Chronic medication with an antifolate drug
- Enrollment in this clinical study in the past 28 days *Each of these symptoms or signs is considered a "danger sign."
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2005
Study Completion
December 1, 2005
Study Registration Dates
First Submitted
July 29, 2005
First Submitted That Met QC Criteria
July 29, 2005
First Posted (Estimate)
August 1, 2005
Study Record Updates
Last Update Posted (Estimate)
August 27, 2010
Last Update Submitted That Met QC Criteria
August 26, 2010
Last Verified
March 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Vector Borne Diseases
- Parasitic Diseases
- Protozoan Infections
- Malaria
- Malaria, Falciparum
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Amebicides
- Filaricides
- Antinematodal Agents
- Anthelmintics
- Folic Acid Antagonists
- Anti-Infective Agents, Urinary
- Renal Agents
- Chloroquine
- Chloroquine diphosphate
- Pyrimethamine
- Sulfadoxine
Other Study ID Numbers
- 05-0012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on sulfadoxine/pyrimethamine
-
Emzor Pharmaceutical Industries LimitedNot yet recruiting
-
Centers for Disease Control and PreventionMinistry of Health and Population, MalawiCompletedHIV Infections | Malaria, FalciparumMalawi
-
Tampere UniversityAcademy of Finland; Foundation for Paediatric Research, FinlandActive, not recruitingSexually Transmitted Diseases | Pregnancy | Preterm Birth | MalariaMalawi
-
University of Cape TownWorld Health Organization; Medical Research Council, South Africa; Global FundCompleted
-
London School of Hygiene and Tropical MedicineMedical Research Council Unit, The GambiaCompletedAsymptomatic P.Falciparum MalariaGambia
-
Centers for Disease Control and PreventionKenya Medical Research Institute; Kenya Ministry of HealthCompleted
-
University of Cape TownWorld Health Organization; Medical Research Council, South AfricaCompleted
-
London School of Hygiene and Tropical MedicineCheikh Anta Diop University, SenegalCompleted
-
London School of Hygiene and Tropical MedicineFobang Institutes Centre for Health Implementation and Translational ResearchRecruiting
-
London School of Hygiene and Tropical MedicineInstitut National de Santé Publique de Côte d'IvoireRecruiting